Page last updated: 2024-11-07

dichlororibofuranosylbenzimidazole and Adenocarcinoma

dichlororibofuranosylbenzimidazole has been researched along with Adenocarcinoma in 2 studies

Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.

Adenocarcinoma: A malignant epithelial tumor with a glandular organization.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Shan, B1
Zhuo, Y1
Chin, D1
Morris, CA1
Morris, GF1
Lasky, JA1
te Poele, RH1
Okorokov, AL1
Joel, SP1

Other Studies

2 other studies available for dichlororibofuranosylbenzimidazole and Adenocarcinoma

ArticleYear
Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells.
    The Journal of biological chemistry, 2005, Jan-14, Volume: 280, Issue:2

    Topics: Adenocarcinoma; Cell Line, Tumor; Culture Media, Conditioned; Cyclin T; Cyclin-Dependent Kinase 9; C

2005
RNA synthesis block by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells.
    Oncogene, 1999, Oct-14, Volume: 18, Issue:42

    Topics: Adenocarcinoma; Apoptosis; Cell Survival; Clone Cells; Colonic Neoplasms; Dichlororibofuranosylbenzi

1999